Bibliography
- Link to National Plan to Address Alzheimer's Disease. Available from: http://aspe.hhs.gov/daltcp/napa/NatlPlan.pdf
- Arrowsmith J. Phase II failures: 2008 – 2010. Nat Rev Drug Discov 2011;10:1
- Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712-13
- Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature 2012;483:531-3
- Leeson PD, St-Gallay SA. The influence of the ‘organizational factor' on compound quality in drug discovery. Nat Rev Drug Discov 2011;10:749-65
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
- Wager TT, Chandrasekaran RY, Hou X, Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010;1:420-34
- Ghose AK, Herbertz T, Hudkins RL, Knowledge-based, Central Nervous System (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 2012;3:50-68
- Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in centralnervous system disorders. Nat Rev Drug Discov 2009;8:892-909
- Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200
- Allen J, Jeffrey P, Williams R, Ratcliffe AR. Approaches to assessing drug safety in the discovery phase. Drugs Future 2010;35:67-75